1. Ревматология: Национальное руководство. Под ред. Е.Л.Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008; с. 355–67.
2. Alamanos Y, Papadopoulos NG, Voulgari PV et al. Epidemiology of psoriatic arthritis in northwest Greece. J Rheumatol 2003; 30: 2641–4.
3. Soderlin MK, Borjesson O, Kautianen H et al. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002; 61: 911–5.
4. O’Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol 1994; 8 (2): 245–61.
5. Salvarani C, Cantini F, Olivieri I et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49: 541–5.
6. Salvarani C, Pipitone N, Catanoso M et al. Adalimumab in psoriatic arthritis. J Rheumatol Suppl. 2012; 89: 77–81.
7. Husted MR, Reda DJ, Farewell VT. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151–8.
8. Gladman D, Mease P, Rithlin C et al. Adalimumab improves joint-and skin-related functional impairment in patients with psoriatic arthritis: Patients-reported outcomes of the Adalimumab effectiveness in psoriatic arthritis trials (ADEPT). Ann Rheum Dis 2006; 9: 1–6.
9. Ibrahim G, Groves C, Chandramohan M et al. Clinical Study Clinical and Ultrasound Examination of the Leeds Enthesitis Index in Psoriatic Arthritis and Rheumatoid Arthritis. ISRN Rheumatology 2011; Article ID 731917.
10. McHugh N, Balachrishnan C, Jones S. Progression of peripheral joint disease in PsA: a 5 year prospective study. Rheumatology 2003; 42: 778–83.
11. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387–94.
12. Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71 (1): 4–12.
13. Soriano E, McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. 
A systematic review. J Rheum 2006; 33: 1–9.
14. Ritchlin Ch, Mease Ph, Perdok R et al. Is Adalimumab an effecacious treatment for enthesitis of the Achilles tendon in patients with Spondyloarthritis? Arthritis Rheum 2009; 60 (Suppl. 10): 1778.
15. Harty L, Veale В. How early should psoriatic arthritis be treated with a TNF-bloker? Curr Opin Rheu 2010; 22: 393–6.
16. Genovese M, Mease P, Thomas G et al. Safety and efficacy of Adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34: 1040–50.
17. Gladman D, Mease P, Ritchlin Ch et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56 (2): 476–88.
18. Mease P, Gladman D, Ritchlin C et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthr Rheum 2005; 52 (10): 
279–89.
19. Mease P, Ory P, Sharp J et al Adalimumab for long-term treatment psoriatic arthritis: 
2-year data from the Adalimumab Effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009; 68: 702–9.
20. Mease P, Wei N, Fudman EJ et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containinga tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Reumatol 2010; 37 (4): 692–703.
21. McHugh N, Van den Bosch F., Manger B et al. Adalimumab (Humira®) Treatment is Effective in patients with Psoriatic Arthritis (PsA) in Day-to-Day Clinical Practice – Results from the STEREO Trial. 25th Annual General Meeting of the British Society for Rheumatology (BSR), UK, Liverpool 2008; Abs. 259.
22. McHugh N, Van der Bosch F, Roedevand E et al. Effective treatment for joint and skin symptoms with Adalimumab in combination with various DMARDs in patients with psoriatic arthritis: results of the STEREO trial. 26th Annual General Meeting of the British Society for Rhe OP 21, 2009.
23. Gladman D, Sampalis JS, Illouz O, Gueratte B. Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study. J Rheumatol 2010; 37 (9).
24. Коротаева Т.В., Логинова Е.Ю., Новикова Д.С. и др. Влияние ингибитора фактора некроза опухоли-альфа на клиническую активность, реологические свойства крови и состояние артериальной стенки при псориатическом артрите. Научно-практическая ревматология. 2010; 3: 36–41.
25. Karanikolas GN, Kouki EM, Katsalira A et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011; 38 (11): 2466–74.
26. Rudwaleit M, Van den Bosch F, Kron M et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12 (3): 117.
27. Rodgers M, Epstein D, Bojke L et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011; 15 (10): 301–29.
28. Saougou I, Markatseli T, Papagoras C et al. Sustained clinical response in psoriatic patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40 (5): 398–406.

Т.В.Коротаева
ФГБУ Научно-исследовательский институт ревматологии РАМН, Москва